As a proud co‑organiser, curATime looks back on TFmed 2026 as a strong example of how collaboration across innovation clusters can amplify scientific progress. The joint organisation with the Clusers4Future PROXIDRUGS and CNATM highlighted complementary expertise in RNA technologies, drug development, and translational research, creating a unique environment for interdisciplinary dialogue.
The conference programme reflected this diversity, covering a broad spectrum of therapeutic frontiers — from novel nucleic acid–based modalities and delivery technologies to immunology, oncology, and disease‑driven translational approaches. TFmed thus served not only as a conference, but as a living interface between discovery, development, and application.
TFmed 2026 featured particularly strong engagement from the curATime core partners, including TRON, University Medical Center Mainz, and the German Research Center for Artificial Intelligence (DFKI). Their scientific contributions underlined the depth and breadth of expertise within the curATime consortium and its commitment to translation‑driven research.
The conference also marked an important milestone for curATime Phase 2, with active participation from new partners joining the cluster. Inspiring talks and poster presentations by Robert Zweigerdt (Hannover Medical School), as well as Boris Greber and Thomas Berger (Catalent), added valuable perspectives and further enriched the scientific discussions.
curATime extends its sincere thanks to Ivan Đikić, Johnny Kim, and Stefan Engelhardt for bringing people together and helping shape TFmed into a vibrant platform that goes beyond disciplinary and institutional boundaries.
We are proud to host the next TFmed, 2028 in Mainz!
